Biogen Idec Adds Liver Warning To Multiple Sclerosis Therapy Avonex
This article was originally published in The Pink Sheet Daily
Executive Summary
Interferon beta product joins Serono/Pfizer's Rebif with warning reflecting postmarketing experiences. Berlex' Betaseron does not have a warning but recommends testing. Coming on the heels of the Tysabri withdrawal, the labeling change is the second recent setback for Biogen Idec's multiple sclerosis franchise.
You may also be interested in...
Copaxone Reaches MS Market Share High Following Tysabri Withdrawal
Teva’s multiple sclerosis therapy glatiramer gained the leading market position in both total and new prescriptions in March, the company says. Copaxone’s gains followed Biogen Idec/Elan’s marketing suspension of the competing MS therapy Tysabri and the addition of a liver damage warning to Biogen’s Avonex.
Copaxone Reaches MS Market Share High Following Tysabri Withdrawal
Teva’s multiple sclerosis therapy glatiramer gained the leading market position in both total and new prescriptions in March, the company says. Copaxone’s gains followed Biogen Idec/Elan’s marketing suspension of the competing MS therapy Tysabri and the addition of a liver damage warning to Biogen’s Avonex.
Berlex Issues Betaseron Liver Testing Reminder Due To Increased MS Safety Focus
“Dear Health Care Professional” letter is sent to 7,000 physicians reminding them that liver function testing is recommended at one, three and six months following initiation of Betaseron for MS treatment.